farglitazar farglitazar farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by glaxosmithkline, but has never been marketed. it progressed to phase ii clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy. after reaching phase iii for type 2 diabetes, further development was discontinued. farglitazarclinical datapregnancycategory n/a atc codenonelegal statuslegal status development discontinued identifiers iupac name n-(o-benzoylphenyl)-o--l-tyrosine cas number196808-45-4 ypubchem cid170364iuphar/bps2672chemspider148961 yunii3433gy7132keggd04132chemblchembl107367 ycomptox dashboard (epa)dtxsid1047310 chemical and physical dataformulac34h30n2o5molar mass546.623 g·mol−13d model (jsmol)interactive image smiles o=c(c1ccccc1)c2ccccc2n(c(=o)o)cc5ccc(occc3nc(oc3c)c4ccccc4)cc5 inchi inchi=1s/c34h30n2o5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35h,20-22h2,1h3,(h,38,39)/t31-/m0/s1 nkey:zzchhvuqyrmylw-hkbqpedesa-n n ny (what is this?) (verify)